06/08/2026 Biogen completed the acquisition of RayThera to strengthen its immunology pipeline Ono Pharmaceutical entered into a drug discovery partnership with Mediar Therapeutics to create novel antibody therapeutics for fibro-inflammatory diseases Mediar Therapeutics entered into a collaboration and option agreement with Ono Pharmaceutical Biogen completed the acquisition of RayThera to strengthen its immunology pipeline (Ref) Biogen announced the completion of its acquisit

13/05/2026 Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis (Ref) Qureight, an imaging CRO and Mediar Therapeutics announced that Qureight’s AI-powered 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase 2, EncompaSSc trial evaluating MTX-474 (a first in class human mAb, th